BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35257007)

  • 1. GGT5 Is an Independent Prognostic Biomarker in Stomach Adenocarcinoma.
    Huang Y; Zhou H; Zou J; Wang D
    Can J Gastroenterol Hepatol; 2022; 2022():9983351. PubMed ID: 35257007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of stomach adenocarcinoma based on fatty acid metabolism-related genes frofiling.
    Liu C; Tao Y; Lin H; Lou X; Wu S; Chen L
    Front Mol Biosci; 2022; 9():962435. PubMed ID: 36090054
    [No Abstract]   [Full Text] [Related]  

  • 3. GGT5 facilitates migration and invasion through the induction of epithelial-mesenchymal transformation in gastric cancer.
    Luo Z; Chen Y; Chen B; Zhao Z; Wu R; Ren J
    BMC Med Genomics; 2024 Apr; 17(1):82. PubMed ID: 38581025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of
    Wang Y; Fang Y; Zhao F; Gu J; Lv X; Xu R; Zhang B; Fang Z; Li Y
    Front Genet; 2022; 13():810292. PubMed ID: 35368661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.
    Zhao W; Liang Z; Yao Y; Ge Y; An G; Duan L; Yao J
    Cancer Immunol Immunother; 2024 May; 73(7):131. PubMed ID: 38748299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VGLL3 is a prognostic biomarker and correlated with clinical pathologic features and immune infiltrates in stomach adenocarcinoma.
    Zhang L; Li L; Mao Y; Hua D
    Sci Rep; 2020 Jan; 10(1):1355. PubMed ID: 31992826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data.
    Zhang X; Liang Y
    Biomed Res Int; 2021; 2021():8197936. PubMed ID: 33506034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.
    Yuan Q; Zhou Q; Ren J; Wang G; Yin C; Shang D; Xia S
    Cancer Med; 2021 Jun; 10(12):4004-4016. PubMed ID: 33982398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer.
    Gu W; Sun H; Zhang M; Mo S; Tan C; Ni S; Yang Z; Wang Y; Sheng W; Wang L
    Cancer Med; 2023 Jan; 12(2):1520-1531. PubMed ID: 35864742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased expression of SEMA5B in gastric adenocarcinoma predicts poor prognosis: a study based on TCGA data].
    Cao H; Song XK; Hong YG
    Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):856-860. PubMed ID: 34407591
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of ITGB1-DT expression delays the growth and migration of stomach adenocarcinoma and improves the prognosis of cancer patients using the bioinformatics and cell model analysis.
    Jiang N; Guo Q; Luo Q
    J Gastrointest Oncol; 2022 Apr; 13(2):615-629. PubMed ID: 35557569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a 14-lncRNA Signature and Construction of a Prognostic Nomogram Predicting Overall Survival of Gastric Cancer.
    Nie K; Deng Z; Zheng Z; Wen Y; Pan J; Jiang X; Yan Y; Liu P; Liu F; Li P
    DNA Cell Biol; 2020 Sep; 39(9):1532-1544. PubMed ID: 32644844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma.
    Ye Z; Zheng M; Zeng Y; Wei S; Huang H; Wang Y; Liu Q; Lin Z; Chen S; Zheng Q; Chen L
    Front Oncol; 2021; 11():612952. PubMed ID: 34235071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Expression of the Component 3a Receptor 1 (C3AR1) Gene in Stomach Adenocarcinomas Infers a Poor Prognosis and High Immune-Infiltration Levels.
    Yang H; Li L; Liu X; Zhao Y
    Med Sci Monit; 2021 Feb; 27():e927977. PubMed ID: 33539329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Expression of ERK-related RASGRF2 predicts Poor prognosis in patients with Stomach Adenocarcinoma and correlates with M2 macrophage.
    Du Y; Wang Z; Wan W
    J Cancer; 2021; 12(23):7177-7189. PubMed ID: 34729119
    [No Abstract]   [Full Text] [Related]  

  • 17. Sarcopenia and a 5-mRNA risk module as a combined factor to predict prognosis for patients with stomach adenocarcinoma.
    Yang H; Tian W; Zhou B
    Genomics; 2022 Jan; 114(1):361-377. PubMed ID: 34933074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Construction of a Long Noncoding RNA Prognostic Risk Model for Stomach Adenocarcinoma Patients.
    Zha Z; Zhang P; Li D; Liu G; Lu L
    Dis Markers; 2021; 2021():8895723. PubMed ID: 33680217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening lncRNAs with diagnostic and prognostic value for human stomach adenocarcinoma based on machine learning and mRNA-lncRNA co-expression network analysis.
    Li Q; Liu X; Gu J; Zhu J; Wei Z; Huang H
    Mol Genet Genomic Med; 2020 Nov; 8(11):e1512. PubMed ID: 33002344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAGED4B is a Poor Prognostic Marker of Stomach Adenocarcinoma and a Potential Therapeutic Target for Stomach Adenocarcinoma Tumorigenesis.
    Luo WZ; Li X; Wu XX; Shang YW; Meng DH; Chen YL; Zhang QS
    Int J Gen Med; 2023; 16():1681-1693. PubMed ID: 37181643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.